Show simple item record

dc.contributor.authorJanakiraman, R
dc.date.accessioned2020-03-13T04:49:13Z
dc.date.available2020-03-13T04:49:13Z
dc.date.issued2016
dc.identifier.issn0300-8495
dc.identifier.urihttp://hdl.handle.net/10072/392326
dc.description.abstractWe thank Dr Main for his valuable comments regarding the use of antidepressants as analgesics. As Dr Main has correctly mentioned, most of the clinical trails on the effectiveness of duloxetine in chronic pain management were performed by the manufacturers of duloxetine, which is a funding bias. Lunn, Hughes and Wiffen have concluded that there is moderate-quality evidence in managing pain in diabetic peripheral neuropathy with a dose of 60 mg and 120 mg of duloxetine.8
dc.publisher.urihttps://www.racgp.org.au/afp/2016/july/letters-to-the-editor/
dc.relation.ispartofpagefrom458
dc.relation.ispartofpageto460
dc.relation.ispartofissue7
dc.relation.ispartofjournalAustralian Family Physician
dc.relation.ispartofvolume45
dc.subject.fieldofresearchClinical Sciences
dc.subject.fieldofresearchPublic Health and Health Services
dc.subject.fieldofresearchcode1103
dc.subject.fieldofresearchcode1117
dc.titleReply
dc.typeJournal article
dc.type.descriptionC2 - Articles (Other)
dcterms.bibliographicCitationJanakiraman, R, Reply, Australian Family Physician, 2016, 45 (7), pp. 458-460
dc.date.updated2020-03-13T04:45:11Z
dc.description.versionVersion of Record (VoR)
gro.rights.copyright© 2016 Australian Family Physician. Reproduced with permission. Permission to reproduce must be sought from the publisher, The Royal Australian College of General Practitioners.
gro.hasfulltextFull Text
gro.griffith.authorJanakiraman, Raguraman


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record